ESOPHAGOGASTRIC ADENOCARCINOMA
Clinical trials for ESOPHAGOGASTRIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ESOPHAGOGASTRIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ESOPHAGOGASTRIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple therapy aims to boost Cancer-Free survival after surgery for HER2-Positive stomach cancer
Disease control OngoingThis phase II trial tests whether adding pembrolizumab (Keytruda) and trastuzumab (Ontruzant) to standard FLOT chemotherapy, given before and after surgery, can improve outcomes for people with HER2-positive esophagogastric adenocarcinoma. Participants receive the drug combinatio…
Matched conditions: ESOPHAGOGASTRIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo therapy aims to shrink HER2+ stomach tumors before surgery
Disease control OngoingThis study tests whether combining the targeted drug trastuzumab-deruxtecan with other treatments before surgery is safe and feasible for people with HER2-positive stomach or esophagus cancer that has not spread. About 36 adults will receive the drug combinations before their pla…
Matched conditions: ESOPHAGOGASTRIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC